Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurotrophin-3 improves functional constipation.

Henry P Parkman1, Satish S C Rao, James C Reynolds

  • 1Temple University Hospital, Philadelphia, Pennsylvania 19140, USA.

The American Journal of Gastroenterology
|June 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

The American journal of gastroenterology·2026
Same author

Disorders of Gut-Brain Interaction and the Rome V Process.

Gastroenterology·2026
Same author

Gastrointestinal Symptoms and Systemic Comorbidities in Patients With POTS: A Systematic Review and Meta-Analysis.

Neurogastroenterology and motility·2026
Same author

Central and Peripheral Neuromodulators in Functional Dyspepsia and Gastroparesis: A Symptom-Based Clinical Review.

Neurogastroenterology and motility·2026
Same author

Centrally Mediated Disorders of Gastrointestinal Pain.

Gastroenterology·2026
Same author

Bloating, Visible Abdominal Distension, and Other Intestinal Gas-Related Symptoms in Irritable Bowel Syndrome and Functional Dyspepsia.

United European gastroenterology journal·2026
Same journal

Calendar of Courses, Symposiums and Conferences.

The American journal of gastroenterology·2026
Same journal

Molecular Nonendoscopic Tests for the Early Detection of Esophageal Squamous Carcinoma and High-Grade Dysplasia: Promising Progress.

The American journal of gastroenterology·2026
Same journal

ACG Clinical Guideline: Colonic Diverticulitis.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: July 2026.

The American journal of gastroenterology·2026
Same journal

2026 CME Information.

The American journal of gastroenterology·2026
See all related articles

Neurotrophin-3 (NT-3) effectively treated chronic constipation by increasing bowel movement frequency and improving colon transit. This novel therapy demonstrated safety and efficacy in a randomized controlled trial.

Area of Science:

  • Neuroscience
  • Gastroenterology
  • Pharmacology

Background:

  • Neurotrophin-3 (NT-3) is a key neurotrophic factor regulating nervous system development and function.
  • Preliminary research indicated NT-3's potential to enhance gastrointestinal (GI) transit and stool frequency.
  • Chronic constipation affects a significant population, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the dose-dependent effects of NT-3 on bowel function and colon transit in patients with chronic constipation.
  • To assess the efficacy of NT-3 in improving symptoms associated with chronic constipation.
  • To determine the safety profile of NT-3 administration.

Main Methods:

  • A double-blind, randomized, placebo-controlled phase II study involving 107 patients diagnosed with functional constipation.

Related Experiment Videos

  • Participants received subcutaneous injections of placebo or varying doses of NT-3 (3 mg or 9 mg) once or three times weekly for four weeks.
  • Primary endpoint: change in spontaneous, complete bowel movements per week. Colon transit was assessed pre- and post-treatment.

    • Main Results:

    • The 9 mg NT-3 administered three times weekly (TTW) significantly increased spontaneous and total bowel movement frequency compared to placebo.
    • A dose-related improvement in stool consistency and ease of passage was observed with NT-3 TTW.
    • NT-3 TTW reduced infrequent bowel movements, improved colon transit, alleviated constipation symptoms, and showed transient injection-site reactions as the most common adverse event.

    Conclusions:

    • Administering NT-3 three times weekly (TTW) effectively enhances stool frequency and colon transit in patients with chronic constipation.
    • NT-3 demonstrates significant improvement in constipation-related symptoms.
    • NT-3 represents a potentially novel, safe, and effective therapeutic agent for functional constipation.